Pharmaceutical News

RSS

7 in 10 Americans support mandated coverage of birth control medications, shows survey

Nearly 7 in 10 Americans support mandated coverage of birth control medications, according to a new national survey by researchers at the University of Michigan Health System.

23 Apr 2014

UT Southwestern researchers identify potential new treatment for depression

Researchers at UT Southwestern Medical Center are making breakthroughs that could benefit people suffering from depression.

23 Apr 2014

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

Between 10 and 20 percent of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy.

23 Apr 2014

New painkiller, with fewer side-effects, up for FDA approval

The drug, Moxduo, allows patients to take lower doses of other painkillers. Elsewhere, a Food and Drug Administration official talks about another painkiller, Zohydro.

23 Apr 2014

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Bayer HealthCare today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis (NCFB).

23 Apr 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra.

22 Apr 2014

NBTY introduces Nature's Origin, a complete line of nutritional supplements

NBTY, Inc., a leading global manufacturer and distributor of high-quality vitamins and nutritional supplements, introduces Nature's Origin, its first complete line of vitamins, minerals and herbal supplements that are free from ingredients made with GMOs, preservatives, gluten and irradiation.

22 Apr 2014

Doctors must consider factors when administering combination vaccines, say researchers

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive option, according to a new study by University of Illinois researchers.

22 Apr 2014

Vietnam's pharmaceutical market records growth rate of nearly 17% in 2013

Decision Resources Group finds that Vietnam is currently one of the fastest growing pharmaceutical markets in Southeast Asia, recording a growth rate of nearly 17 percent and exceeding $3 billion in size in 2013. Increasing affluence, a rapidly aging population and the steady extension of public health insurance are among factors that are driving demand for prescription medicines.

22 Apr 2014

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Nonsteroidal antinflamatory drugs (NSAIDs) that block an enzyme called COX-2 relieve pain and inflammation but can cause heart attacks, stroke, heart failure, and even sudden cardiac death.

22 Apr 2014

Race to Yes campaign lauds Sarepta's plans to seek FDA approval for Duchenne treatment

The Race to Yes campaign today lauded drug maker Sarepta on its plans to move forward immediately to seek FDA approval of the first drug to successfully treat Duchenne muscular dystrophy, the world's leading genetic killer of children.

22 Apr 2014

Study finds ginseng can help prevent, treat influenza and RSV infection

Ginseng can help treat and prevent influenza and respiratory syncytial virus (RSV), a respiratory virus that infects the lungs and breathing passages, according to research findings by a scientist in Georgia State University's new Institute for Biomedical Sciences.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Global Generic Drugs market to grow at 11.02% CAGR over 2013-2018

Global Information Inc. announces the addition of a new market research report "Global Generic Drugs Market 2014-2018" at GIIResearch.com

21 Apr 2014

Cubist submits ceftolozane/tazobactam NDA for treatment of cUTI and cIAI

Cubist Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for approval of its investigational antibiotic ceftolozane/tazobactam for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI).

21 Apr 2014

FDA grants Orphan Drug Designation to Emergent BioSolutions' BioThrax for PEP of anthrax disease

Emergent BioSolutions Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BioThrax (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis.

21 Apr 2014

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

21 Apr 2014

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML).

21 Apr 2014

Children get codeine in U.S. emergency rooms, despite risks: Study

Despite its potentially harmful effects in children, codeine continues to be prescribed in U.S. emergency rooms, according to new research from UCSF Benioff Children's Hospital San Francisco.

21 Apr 2014

Pharmaceutical News

7 in 10 Americans support mandated coverage of birth control medications, shows survey

UT Southwestern researchers identify potential new treatment for depression

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

New painkiller, with fewer side-effects, up for FDA approval

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

FDA approves Cyramza to treat patients with advanced stomach cancer

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

NBTY introduces Nature's Origin, a complete line of nutritional supplements

Doctors must consider factors when administering combination vaccines, say researchers

Vietnam's pharmaceutical market records growth rate of nearly 17% in 2013

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Race to Yes campaign lauds Sarepta's plans to seek FDA approval for Duchenne treatment

Study finds ginseng can help prevent, treat influenza and RSV infection

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Global Generic Drugs market to grow at 11.02% CAGR over 2013-2018

Cubist submits ceftolozane/tazobactam NDA for treatment of cUTI and cIAI

FDA grants Orphan Drug Designation to Emergent BioSolutions' BioThrax for PEP of anthrax disease

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Children get codeine in U.S. emergency rooms, despite risks: Study

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News